CG Oncology(CGON) - 2025 Q2 - Quarterly Results

Exhibit 99.1 CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - - Announced unanimous verdict that CG Oncology owes no future royalties ...